We're celebrating the year of '23! We help people access, understand and benefit from the human genome.
23andMe Claimed Company
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. read more
HR or Marketing? Claim Your Free Employer Account
Kenneth Hillan — Head of Therapeutics at 23andMe
Executive Bio
Kenneth joined 23andMe in 2019 as Head of Therapeutics. He leads a dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases.
At Achaogen, Hillan served as Chief Executive Officer. He held progressively senior roles at Genentech-Roche including Senior Vice President and Head of Clinical Development and Product Development Strategy Asia-Pacific for Roche in Shanghai, China. He led the medical and scientific strategies for Genentech’s Immunology, Tissue Growth and Repair (ITGR) drug portfolio, and was responsible for numerous drug approvals.
Hillan is a member of the board of directors at Zymeworks. He served on the board of directors at Achaogen, and at Relypsa until it was acquired by Galenica AG in 2016.
He holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the
Faculty of Medicine at the University of Glasgow, U.K. He is a Fellow of the Royal College of Surgeons (FR
At Achaogen, Hillan served as Chief Executive Officer. He held progressively senior roles at Genentech-Roche including Senior Vice President and Head of Clinical Development and Product Development Strategy Asia-Pacific for Roche in Shanghai, China. He led the medical and scientific strategies for Genentech’s Immunology, Tissue Growth and Repair (ITGR) drug portfolio, and was responsible for numerous drug approvals.
Hillan is a member of the board of directors at Zymeworks. He served on the board of directors at Achaogen, and at Relypsa until it was acquired by Galenica AG in 2016.
He holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the
Faculty of Medicine at the University of Glasgow, U.K. He is a Fellow of the Royal College of Surgeons (FR
Executive Team Culture Ratings from 23andMe Employees
TOP
50%
23andMe's Executive Team scores in the Top 50%
of similar sized companies on Comparably
of similar sized companies on Comparably
23andMe's Executive Team at a Glance
Based on 26 ratings, 23andMe's employees are less satisfied with their Executive Team and give them a “C+” or 65/100. On average, Men provided higher ratings for their Executive Team compared to Women.
23andMe's Executive Team ranks in the Bottom 40% of other companies in San Francisco and Top 50% of other companies on Comparably that also have 501-1,000 Employees.
×